Effect of neoadjuvant therapy regimens on lymph nodes yield in rectal cancer.
lymph node
neoadjuvant therapy
rectal cancer
Journal
Journal of surgical oncology
ISSN: 1096-9098
Titre abrégé: J Surg Oncol
Pays: United States
ID NLM: 0222643
Informations de publication
Date de publication:
27 May 2024
27 May 2024
Historique:
received:
19
04
2024
accepted:
24
04
2024
medline:
27
5
2024
pubmed:
27
5
2024
entrez:
27
5
2024
Statut:
aheadofprint
Résumé
Pathological nodal staging is relevant to postoperative decision-making and a prognostic marker of cancer survival. This study aimed to assess the effect of different total neoadjuvant therapy (TNT) regimens on lymph node status following total mesorectal excision (TME) for locally advanced rectal cancer (LARC). A retrospective cohort study of patients treated for node-positive clinical stage 3 LARC with TNT between January 2015 and August 2022. Patients were stratified into induction therapy and consolidation therapy groups. Variables collated included patient demographics, clinical and radiological characteristics of the tumor, and pathology of the resected specimen. Primary outcome was total harvested lymph nodes. Ninety-seven patients were included (57 [58.8%] males; mean age of 58.5 ± 11.4 years). The induction therapy group included 85 (87.6%) patients while 12 (12.4%) patients received consolidation therapy. A median interquartile range value of 22.00 (5.00-72.00) harvested lymph nodes was recorded for the induction therapy group in comparison to 16.00 (16.00-47.00) in the consolidation therapy arm (p = 0.487). Overall pathological complete response rate was 34%. Total harvested nodes from resected specimens were marginally lower in the consolidation therapy group. Induction therapy may be preferrable to optimize postoperative specimen staging.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
Pathological nodal staging is relevant to postoperative decision-making and a prognostic marker of cancer survival. This study aimed to assess the effect of different total neoadjuvant therapy (TNT) regimens on lymph node status following total mesorectal excision (TME) for locally advanced rectal cancer (LARC).
METHODS
METHODS
A retrospective cohort study of patients treated for node-positive clinical stage 3 LARC with TNT between January 2015 and August 2022. Patients were stratified into induction therapy and consolidation therapy groups. Variables collated included patient demographics, clinical and radiological characteristics of the tumor, and pathology of the resected specimen. Primary outcome was total harvested lymph nodes.
RESULTS
RESULTS
Ninety-seven patients were included (57 [58.8%] males; mean age of 58.5 ± 11.4 years). The induction therapy group included 85 (87.6%) patients while 12 (12.4%) patients received consolidation therapy. A median interquartile range value of 22.00 (5.00-72.00) harvested lymph nodes was recorded for the induction therapy group in comparison to 16.00 (16.00-47.00) in the consolidation therapy arm (p = 0.487). Overall pathological complete response rate was 34%.
CONCLUSION
CONCLUSIONS
Total harvested nodes from resected specimens were marginally lower in the consolidation therapy group. Induction therapy may be preferrable to optimize postoperative specimen staging.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209‐249.
Zwart WH, Hotca A, Hospers GAP, Goodman KA, Garcia‐Aguilar J. The multimodal management of locally advanced rectal cancer: making sense of the new data. Am Soc Clin Oncol Educ Book. 2022;42:1‐14.
Chau I, Brown G, Cunningham D, et al. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging–defined poor‐risk rectal cancer. J Clin Oncol. 2006;24:668‐674.
Kasi A, Abbasi S, Handa S, et al. Total neoadjuvant therapy vs standard therapy in locally advanced rectal cancer: a systematic review and meta‐analysis. JAMA Network Open. 2020;3:e2030097.
Edge SB, Compton CC. The American Joint Committee on ancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471‐1474.
Amajoyi R, Lee Y, Recio PJ, Kondylis PD. Neoadjuvant therapy for rectal cancer decreases the number of lymph nodes harvested in operative specimens. Am J Surg. 2013;205:289‐292.
Baxter NN, Morris AM, Rothenberger DA, Tepper JE. Impact of preoperative radiation for rectal cancer on subsequent lymph node evaluation: a population‐based analysis. Int J Radiat Oncol*Biol*Phys. 2005;61:426‐431.
Jin C, Deng X, Li Y, He W, Yang X, Liu J. Lymph node ratio is an independent prognostic factor for rectal cancer after neoadjuvant therapy: a meta‐analysis. J Evid‐Based Med. 2018;11:169‐175.
Kanda Y. Investigation of the freely available easy‐to‐use software ‘EZR’ for medical statistics. Bone Marrow Transpl. 2013;48:452‐458.
Liu S, Jiang T, Xiao L, et al. Total neoadjuvant therapy (TNT) versus standard neoadjuvant chemoradiotherapy for locally advanced rectal cancer: a systematic review and meta‐analysis. Oncologist. 2021;26:e1555‐e1566.
Chapman BC, Lai SH, Friedrich T, et al. Rectal cancer: clinical and molecular predictors of a complete response to total neoadjuvant therapy. Dis Colon Rectum. 2023;66:521‐530.
Gilshtein H, Ghuman A, Dawoud M, et al. Total neoadjuvant treatment for rectal cancer. Am Surg. 2021;87:708‐713.
Horesh N, Freund MR, Garoufalia Z, et al. Total neoadjuvant therapy is a predictor for complete pathological response in patients undergoing surgery for rectal cancer. J Gastrointest Surg. 2022;26:2579‐2584.
Marco MR, Zhou L, Patil S, et al. Consolidation mFOLFOX6 chemotherapy after chemoradiotherapy improves survival in patients with locally advanced rectal cancer: final results of a multicenter phase II trial. Dis Colon Rectum. 2018;61:1146‐1155.
Fokas E, Schlenska‐Lange A, Polat B, et al. Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for patients with locally advanced rectal cancer: long‐term results of the CAO/ARO/AIO‐12 randomized clinical trial. JAMA Oncol. 2022;8:e215445.
Berger AC, Sigurdson ER, LeVoyer T, et al. Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes. J Clin Oncol. 2005;23:8706‐8712.
Al‐Sukhni E, Milot L, Fruitman M, et al. Diagnostic accuracy of MRI for assessment of T category lymph node metastases, and circumferential resection margin involvement in patients with rectal cancer: a systematic review and meta‐analysis. Ann Surg Oncol. 2012;19:2212‐2223.
Gefen R, Garoufalia Z, Horesh N, et al. How reliable is restaging MRI after neoadjuvant therapy in rectal cancer? Colorectal Dis. 2023;25:1631‐1637.
Semon S, Lynch AC, Bressel M, Wise AG, Heriot AG. Optimal pathology processing and reporting‐ systematic review and meta‐analysis of the accuracy of MRI and endorectal ultrasound in the restaging and response assessment of rectal cancer following neoadjuvant therapy. Colorectal Dis. 2015;17:748‐761.
Kye BH, Kim HJ, Kim G, Kim JG, Cho HM. Multimodal assessments are needed for restaging after neoadjunvant chemoradiation therapy in rectal cancer patients. Cancer Res Treatment. 2016;48:561‐566.
Garcia‐Aguilar J, Patil S, Gollub MJ, et al. Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy. J Clin Oncol. 2022;40:2546‐2556.